Navigation Links
BioRestorative Therapies Provides Company Updates with Shareholder Letter
Date:8/1/2013

Vienna, Austria. Mr. Silva presented the Company's research on Human Metabolically Active Brown Adipose Tissue Derived Stem Cells. This research is a result of the scientific work the Company has been performing pursuant to its ThermoStem® Program.  
  • The Company hired ProActive Capital in mid-April to help increase awareness of the Company among the investment community.  ProActive Capital is also helping to increase exposure through the use of social and digital media.
  • In mid April, the Company implemented a 1-for-50 reverse stock split which reduced its outstanding shares from 820,641,011 to 16,412,820. 94% of the shares voted were in favor of the proposal. The Company believes the reverse split will help attract a new base of shareholders as well as new institutional and retail support in the market.
  • In mid May, the Company signed an agreement with Dexterity, Inc., a product design and bioengineering firm, to further the development and production of its brtxDISC™ (Disc Implanted Stem Cells) stem cell therapy device.  This device plays an integral role in delivering stem cells for its proprietary bulging/herniated disc therapy.
  • In May, the Company once again presented its investment thesis at the Marcum MicroCap Conference.  To listen to the webcast, please visit http://wsw.com/webcast/marcum/brtx. The event hosted nearly 100 publicly traded companies with capitalizations under $500 million and attracted more than 1,000 people, including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace.
  • At the end of May, the Company formally launched its "brtx-C Cosmetic" Program. The Company announced that it has developed a human cellular-derived extract that, per initial in v
    '/>"/>

  • SOURCE BioRestorative Therapies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
    2. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
    3. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
    4. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
    5. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
    6. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
    7. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
    8. BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
    9. BioRestorative Therapies Announces Launch of New Website
    10. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
    11. BioRestorative Therapies Announces the Development of an Extract that has Promise for Use in Beauty Care Products
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
    (Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
    (Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
    (Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
    Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
    ... Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... of Defense (DOD) contract to develop its human neural ... tumors. The research contract, entitled "Research to Treat Cancerous ... out in collaboration with Principal Investigator John Zhang, MD, ...
    ... 2011 Cambrex Corporation (NYSE: CBM ) reports second ... Highlights Reported sales increased by ... compared to the second quarter of 2010. EBITDA was $13.2 ... compared to $12.1 million in the second quarter of 2010. ...
    ... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ... on Monday, August 8, 2011, after the U.S. financial markets ... webcast on Monday, August 8, 2011, at 5:00 p.m. Eastern ... and highlights.  A live webcast of the call will be ...
    Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Cambrex Reports Second Quarter of 2011 Results 2Cambrex Reports Second Quarter of 2011 Results 3Cambrex Reports Second Quarter of 2011 Results 4Cambrex Reports Second Quarter of 2011 Results 5Cambrex Reports Second Quarter of 2011 Results 6Cambrex Reports Second Quarter of 2011 Results 7Cambrex Reports Second Quarter of 2011 Results 8Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2
    (Date:10/22/2014)... DENVER , Oct. 20, 2014  Leading identity ... years time half of the world,s population will have ... in Europe . Asia ... dominate the market accounting for more than 60% of ... Acuity,s report  -- "The Global National ...
    (Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
    (Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
    Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
    ... Troy, N.Y. Engineering researchers at Rensselaer Polytechnic Institute ... diverse areas to help create a closed-loop artificial pancreas. ... administer insulin to patients with Type 1 diabetes, and ... living with the chronic disease. For six years, ...
    ... A study conducted by VTT Technical Research Centre of Finland ... grades 95E10 and 98E5 sold in Finland as regards fuel ... tests conducted by VTT using six used cars of different ... claimed in public that fuel consumption is significantly higher with ...
    ... a low-cost healthy lifestyle program, including self-weighing weekly or ... them from gaining too much weight during early pregnancy. ... Endocrine Society,s 93rd Annual Meeting in Boston. "Preventing ... health of all mothers and their babies and can ...
    Cached Biology News:Engineering new weapons in the fight against juvenile diabetes 2Engineering new weapons in the fight against juvenile diabetes 3VTT: No significant difference in car fuel consumption between E10 and E5 petrol grades 2Pregnant women can prevent excess weight gain with simple steps, study finds 2
    ... a concentrated formulation of a rinsing buffer ... technology, as well as for manual immunostaining. ... Brigati M.D., Department of Pathology, University of ... recommended for all the rinsing steps performed ...
    ... MALDI O-TOF creates a new category for ... platform that has been licensed to the ... Manitoba. , As the first single MALDI-TOF ... collisional cooling, the prOTOF 2000 represents a ...
    ... miVac DNA is an ideal small concentrator ... concentrator capable of removing water and organic ... including tubes, microplates, vials and round bottom ... for the busy lab. ,The built-in special ...
    ... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
    Biology Products: